1. A compound of formula (IA), or a solvate, pharmaceutically acceptable salt, ester, amide, complex, chelate, stereoisomer, stereoisomeric mixture, geometric isomer, crystalline or amorphous form, metabolite, metabolic precursor or prodrug thereof:



(IA)

wherein, R_3, R_4 and R_5 are independently selected from hydrogen, hydroxy and C_1-C_6alkoxy, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof, with the proviso that R_3, R_4 and R_5 cannot all be hydrogen.

2. A compound of formula (IA) according to claim 1, or a solvate, pharmaceutically acceptable salt thereof, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof.

3. A compound of formula (IA) according to claim 1, or a solvate, pharmaceutically acceptable salt thereof, wherein, R_4 and R_5 are independently selected from hydroxy and C_1-C_6alkoxy, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof.

4. A compound of formula (IA) according to claim 1, or a solvate, pharmaceutically acceptable salt thereof, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof, wherein, R_3 is hydrogen, R_4 and R_5 are independently selected from hydroxy and C_1-C_6alkoxy.

5. A compound of formula (IA) according to claim 1, or a solvate, pharmaceutically acceptable salt, ester, amide, complex, chelate, stereoisomer, stereoisomeric mixture, geometric isomer, crystalline or amorphous form, metabolite, metabolic precursor or prodrug thereof, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof, wherein, R_3 is hydrogen, R_4 and R_5 are independently selected from C_1-C_6alkoxy.

6. A compound of formula (IA) according to claim 1, or a solvate, pharmaceutically acceptable salt thereof, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof, wherein, R_3 is hydrogen, R_4 and R_5 are independently selected from C_1-C_6alkoxy.

7. A compound of formula (IA) according to claim 1, or a solvate, pharmaceutically acceptable salt, ester, amide, complex, chelate, stereoisomer, stereoisomeric mixture, geometric isomer, crystalline or

amorphous form, metabolite, metabolic precursor or prodrug thereof, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof, wherein, R_3 is hydrogen, R_4 and R_5 are C_1alkoxy.

8. A compound of formula (IA) according to claim 1, or a solvate, pharmaceutically acceptable salt thereof, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof, wherein, R_3 is hydrogen, R_4 and R_5 are C_1alkoxy.

9. A compound of formula (IB), or a solvate, pharmaceutically acceptable salt, ester, amide, complex, chelate, stereoisomer, stereoisomeric mixture, geometric isomer, crystalline or amorphous form, metabolite, metabolic precursor or prodrug thereof:



(IB)

wherein, R_3, R_4 and R_5 are independently selected from hydrogen, hydroxy and C_1-C_6alkoxy, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof, with the proviso that R_3, R_4 and R_5 cannot all be hydrogen.

10. A compound of formula (IB) according to claim 9, or a solvate, pharmaceutically acceptable salt thereof, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof.

11. A compound of formula (IB) according to claim 9, or a solvate, pharmaceutically acceptable salt thereof, wherein, R_4 and R_5 are independently selected from hydroxy and C_1-C_6alkoxy, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof.

12. A compound of formula (IB) according to claim 9, or a solvate, pharmaceutically acceptable salt thereof, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof, wherein, R_3 is hydrogen, R_4 and R_5 are independently selected from hydroxy and C_1-C_6alkoxy.

13. A compound of formula (IB) according to claim 9, or a solvate, pharmaceutically acceptable salt, ester, amide, complex, chelate, stereoisomer, stereoisomeric mixture, geometric isomer, crystalline or amorphous form, metabolite, metabolic precursor or prodrug thereof, including isolated enantiomeric,

diastereomeric and geometric isomers thereof, and mixtures thereof, wherein, R_3 is hydrogen, R_4 and R_5 are independently selected from C_1-C_6alkoxy.

14. A compound of formula (IB) according to claim 9, or a solvate, pharmaceutically acceptable salt thereof, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof, wherein, R_3 is hydrogen, R_4 and R_5 are independently selected from C_1-C_6alkoxy.

15. A compound of formula (IB) according to claim 9, or a solvate, pharmaceutically acceptable salt, ester, amide, complex, chelate, stereoisomer, stereoisomeric mixture, geometric isomer, crystalline or amorphous form, metabolite, metabolic precursor or prodrug thereof, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof, wherein, R_3 is hydrogen, R_4 and R_5 are C_1alkoxy.

16. A compound of formula (IB) according to claim 9, or a solvate, pharmaceutically acceptable salt thereof, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof, wherein, R_3 is hydrogen, R_4 and R_5 are C_1alkoxy.

17. A compound of formula (IC), or a solvate, pharmaceutically acceptable salt, ester, amide, complex, chelate, stereoisomer, stereoisomeric mixture, geometric isomer, crystalline or amorphous form, metabolite, metabolic precursor or prodrug thereof:



(IC)

wherein, R_3, R_4 and R_5 are independently selected from hydrogen, hydroxy and C_1-C_6alkoxy, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof, with the proviso that R_3, R_4 and R_5 cannot all be hydrogen.

18. A compound of formula (IC) according to claim 17, or a solvate, pharmaceutically acceptable salt thereof, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof.

19. A compound of formula (IC) according to claim 17, or a solvate, pharmaceutically acceptable salt thereof, wherein, R_4 and R_5 are independently selected from hydroxy and C_1-C_6alkoxy, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof.

20. A compound of formula (IC) according to claim 17, or a solvate, pharmaceutically acceptable salt thereof, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof, wherein, R_3 is hydrogen, R_4 and R_5 are independently selected from hydroxy and C_1-C_6alkoxy.

21. A compound of formula (IC) according to claim 17, or a solvate, pharmaceutically acceptable salt, ester, amide, complex, chelate, stereoisomer, stereoisomeric mixture, geometric isomer, crystalline or amorphous form, metabolite, metabolic precursor or prodrug thereof, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof, wherein, R_3 is hydrogen, R_4 and R_5 are independently selected from C_1-C_6alkoxy.

22. A compound of formula (IC) according to claim 17, or a solvate, pharmaceutically acceptable salt thereof, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof, wherein, R_3 is hydrogen, R_4 and R_5 are independently selected from C_1-C_6alkoxy.

23. A compound of formula (IC) according to claim 17, or a solvate, pharmaceutically acceptable salt, ester, amide, complex, chelate, stereoisomer, stereoisomeric mixture, geometric isomer, crystalline or amorphous form, metabolite, metabolic precursor or prodrug thereof, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof, wherein, R_3 is hydrogen, R_4 and R_5 are C_1alkoxy.

24. A compound of formula (IC) according to claim 17, or a solvate, pharmaceutically acceptable salt thereof, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof, wherein, R_3 is hydrogen, R_4 and R_5 are C_1alkoxy.

25. A compound of formula (ID), or a solvate, pharmaceutically acceptable salt, ester, amide, complex, chelate, stereoisomer, stereoisomeric mixture, geometric isomer, crystalline or amorphous form, metabolite, metabolic precursor or prodrug thereof:



(ID)

wherein, R_3, R_4 and R_5 are independently selected from hydrogen, hydroxy and C_1-C_6alkoxy, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof, with the proviso that R_3, R_4 and R_5 cannot all be hydrogen.

26. A compound of formula (ID) according to claim 25, or a solvate, pharmaceutically acceptable salt thereof, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof.

27. A compound of formula (ID) according to claim 25, or a solvate, pharmaceutically acceptable salt thereof, wherein, R_4 and R_5 are independently selected from hydroxy and C_1-C_6alkoxy, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof.

28. A compound of formula (ID) according to claim 25, or a solvate, pharmaceutically acceptable salt thereof, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof, wherein, R_3 is hydrogen, R_4 and R_5 are independently selected from hydroxy and C_1-C_6alkoxy.

29. A compound of formula (ID) according to claim 25, or a solvate, pharmaceutically acceptable salt, ester, amide, complex, chelate, stereoisomer, stereoisomeric mixture, geometric isomer, crystalline or amorphous form, metabolite, metabolic precursor or prodrug thereof, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof, wherein, R_3 is hydrogen, R_4 and R_5 are independently selected from C_1-C_6alkoxy.

30. A compound of formula (ID) according to claim 25, or a solvate, pharmaceutically acceptable salt thereof, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof, wherein, R_3 is hydrogen, R_4 and R_5 are independently selected from C_1-C_6alkoxy.

31. A compound of formula (ID) according to claim 25, or a solvate, pharmaceutically acceptable salt, ester, amide, complex, chelate, stereoisomer, stereoisomeric mixture, geometric isomer, crystalline or amorphous form, metabolite, metabolic precursor or prodrug thereof, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof, wherein, R_3 is hydrogen, R_4 and R_5 are C_1alkoxy.

32. A compound of formula (ID) according to claim 25, or a solvate, pharmaceutically acceptable salt thereof, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof, wherein, R_3 is hydrogen, R_4 and R_5 are C_1alkoxy.

33. A compound of formula (IE), or a solvate, pharmaceutically acceptable salt, ester, amide, complex, chelate, stereoisomer, stereoisomeric mixture, geometric isomer, crystalline or amorphous form, metabolite, metabolic precursor or prodrug thereof:



(IE)

wherein, R_4 and R_5 are independently selected from hydrogen, hydroxy and C_1-C_6alkoxy, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof, with the proviso that R_4 and R_5 cannot all be hydrogen.

34. A compound of formula (IE) according to claim 33, or a solvate, pharmaceutically acceptable salt thereof, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof.

35. A compound of formula (IE) according to claim 33, or a solvate, pharmaceutically acceptable salt thereof, wherein, R_4 and R_5 are independently selected from hydroxy and C_1-C_6alkoxy, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof.

36. A compound of formula (IE) according to claim 33, or a solvate, pharmaceutically acceptable salt thereof, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof, wherein, R_4 and R_5 are independently selected from hydroxy and C_1-C_3alkoxy.

37. A compound of formula (IE) according to claim 33, or a solvate, pharmaceutically acceptable salt, ester, amide, complex, chelate, stereoisomer, stereoisomeric mixture, geometric isomer, crystalline or amorphous form, metabolite, metabolic precursor or prodrug thereof, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof, wherein, R_4 and R_5 are independently selected from C_1-C_6alkoxy.

38. A compound of formula (IE) according to claim 33, or a solvate, pharmaceutically acceptable salt thereof, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof, wherein, R_4 and R_5 are independently selected from C_1-C_3alkoxy.

39. A compound of formula (IE) according to claim 33, or a solvate, pharmaceutically acceptable salt, ester, amide, complex, chelate, stereoisomer, stereoisomeric mixture, geometric isomer, crystalline or

amorphous form, metabolite, metabolic precursor or prodrug thereof, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof, wherein, R_4 and R_5 are C_1alkoxy.

40. A compound of formula (IE) according to claim 33, or a solvate, pharmaceutically acceptable salt thereof, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof, wherein, R_4 and R_5 are C_1alkoxy.

41. A compound, or mixture comprising compounds, or a solvate, or pharmaceutically acceptable salt thereof, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof, selected from the group consisting of:

	Structure	Chemical name
		(1R,2R)/(1S,2S)-2-[(3R)/(3S)-Hydroxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)-cyclohexane
		(1R,2R)/(1S,2S)-2-[(3R)-Hydroxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)-cyclohexane
		(1R,2R)/(1S,2S)-2-[(3S)-Hydroxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)-cyclohexane
		(1R,2R)-2-[(3R)-Hydroxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)-cyclohexane
		(1R,2R)-2-[(3S)-Hydroxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)-cyclohexane
		(1R,2S)-2-[(3R)-Hydroxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)-cyclohexane

		(1R,2S)-2-[(3S)-Hydroxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)-cyclohexane
		(1S,2R)-2-[(3R)-Hydroxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)-cyclohexane
		(1S,2R)-2-[(3S)-Hydroxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)-cyclohexane
		(1S,2S)-2-[(3R)-Hydroxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)-cyclohexane
		(1S,2S)-2-[(3S)-Hydroxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)-cyclohexane
		(1R,2S)/(1S,2R)-2-[(3R)/(3S)-Hydroxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)-cyclohexane

42. A compound, or mixture comprising compounds, or a solvate thereof, selected from the group consisting of:

	Structure	**Chemical name**
		(1R,2R)-2-[(3R)-Hydroxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)-cyclohexane monohydrochloride

		(1S,2S)-2-[(3R)-Hydroxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)-cyclohexane monohydrochloride
		(1R,2R)/(1S,2S)-2-[(3R)/(3S)-Hydroxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)-cyclohexane monohydrochloride
		(1R,2R)/(1S,2S)-2-[(3R)-Hydroxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)-cyclohexane monohydrochloride
		(1R,2R)/(1S,2S)-2-[(3S)-Hydroxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)-cyclohexane monohydrochloride
		(1R,2R)-2-[(3S)-Hydroxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)-cyclohexane monohydrochloride
		(1S,2S)-2-[(3S)-Hydroxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)-cyclohexane monohydrochloride

43. A compound which is (1R,2R)-2-[(3R)-Hydroxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)-cyclohexane, or a pharmaceutically acceptable salt thereof, or a solvate thereof.

44. A compound which is (1R,2R)-2-[(3S)-Hydroxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)-cyclohexane, or a pharmaceutically acceptable salt thereof, or a solvate thereof.

45. A compound which is (1S,2S)-2-[(3R)-Hydroxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)-cyclohexane, or a pharmaceutically acceptable salt thereof, or a solvate thereof.

46. A compound which is (1S,2S)-2-[(3S)-Hydroxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)-cyclohexane, or a pharmaceutically acceptable salt thereof, or a solvate thereof.

47. A compound which is (1R,2R)-2-[(3R)-Hydroxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)-cyclohexane monohydrochloride, or a solvate thereof.

48. A compound which is (1R,2R)-2-[(3S)-Hydroxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)-cyclohexane monohydrochloride, or a solvate thereof.

49. A compound which is (1S,2S)-2-[(3R)-Hydroxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)-cyclohexane monohydrochloride, or a solvate thereof.

50. A compound which is (1S,2S)-2-[(3S)-Hydroxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)-cyclohexane monohydrochloride, or a solvate thereof.

51. A composition comprising a compound according to any one of claims 1 to 50 in combination with a pharmaceutically acceptable carrier, excipient or diluent.

52. Use of a compound according to any one of claims 1 to 50 or a composition of claim 51 in the manufacture of a medicament.

53. A method for modulating ion channel activity in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof, an effective amount of a compound according to any one of claims 1 to 50, or a composition of claim 51, or a medicament manufactured according to claim 52.

54. A method for modulating ion channel activity in an *in vitro* setting comprising administering *in vitro* an effective amount of a compound according to any one of claims 1 to 50, or a composition of claim 51, or a medicament manufactured according to claim 52.

55. A method for blocking/inhibiting the activity/conductance of an ion channel in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof, an effective amount of a compound according to any one of claims 1 to 50, or a composition of claim 51, or a medicament manufactured according to claim 52.

56. A method for blocking/inhibiting the activity/conductance of an ion channel in an *in vitro* setting

comprising administering *in vitro* an effective amount of a compound according to any one of claims 1 to 50, or a composition of claim 51, or a medicament manufactured according to claim 52.

57. The method of claims 53, 54, 55 or 56, wherein said ion channel is a potassium channel.

58. The method of claim 57, wherein said potassium channel is a voltage-activated potassium channel.

59. A method for modulating cardiac early repolarising currents and cardiac sodium currents in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof, an effective amount of a compound according to any one of claims 1 to 50, or a composition of claim 51, or a medicament manufactured according to claim 52.

60. A method for blocking/inhibiting cardiac early repolarising currents and cardiac sodium currents in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof, an effective amount of a compound according to any one of claims 1 to 50, or a composition of claim 51, or a medicament manufactured according to claim 52.

61. A method for blocking/inhibiting the cardiac ion channels responsible for the cardiac early repolarising currents and cardiac sodium currents in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof, an effective amount of a compound according to any one of claims 1 to 50, or a composition of claim 51, or a medicament manufactured according to claim 52.

62. A method for blocking/inhibiting cardiac early repolarising currents and cardiac sodium currents in a warm-blooded animal under conditions where an arrhythmogenic substrate is present in the heart of said warm-blooded animal comprising administering to a warm-blooded animal in need thereof, an effective amount of a compound according to any one of claims 1 to 50, or a composition of claim 51, or a medicament manufactured according to claim 52.

63. A method for blocking/inhibiting the cardiac ion channels responsible for the cardiac early repolarising currents and cardiac sodium currents in a warm-blooded animal under conditions where an arrhythmogenic substrate is present in the heart of said warm-blooded animal comprising administering to a warm-blooded animal in need thereof, an effective amount of a compound according to any one of claims 1 to 50, or a composition of claim 51, or a medicament manufactured according to claim 52.

64. The method of claims 59 to 63, wherein said cardiac early repolarising currents comprise ionic currents which activate rapidly after depolarisation of membrane voltage and which effect repolarisation of the cell.

65. The method of claims 59 to 64, wherein said early repolarising currents comprise the cardiac

transient outward potassium current (I_{to}) and/or the ultrarapid delayed rectifier current (I_{Kur}).

66. The method of claim 65, wherein the cardiac transient outward potassium current (I_{to}) and/or the ultrarapid delayed rectifier current (I_{Kur}) comprise at least one of the Kv4.2, Kv4.3, Kv2.1, Kv1.4 and Kv1.5 currents.

67. A method for treating and/or preventing arrhythmia in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof, an effective amount of a compound according to any one of claims 1 to 50, or a composition of claim 51, or a medicament manufactured according to claim 52.

68. A pharmaceutical composition comprising an amount of a compound according to claims 1 to 50 effective to treat and/or prevent atrial arrhythmia in a warm-blooded animal in need of the treatment and/or prevention, and a pharmaceutically acceptable carrier, diluent, or excipient.

69. A method for treating and/or preventing atrial arrhythmia in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 50, or a composition of claim 51, or a medicament manufactured according to claim 52.

70. A method for treating and/or preventing ventricular arrhythmia in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 50, or a composition of claim 51, or a medicament manufactured according to claim 52.

71. A pharmaceutical composition comprising an amount of a compound according to claims 1 to 50 effective to treat and/or prevent ventricular arrhythmia in a warm-blooded animal in need of the treatment and/or prevention, and a pharmaceutically acceptable carrier, diluent, or excipient.

72. A method for treating and/or preventing atrial fibrillation in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 50, or a composition of claim 51, or a medicament manufactured according to claim 52.

73. A method for treating and/or preventing atrial flutter in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 50, or a composition of claim 51, or a medicament manufactured according to claim 52.

74. A method for treating and/or preventing ventricular fibrillation in a warm-blooded animal

comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 50, or a composition of claim 51, or a medicament manufactured according to claim 52.

75. A method for treating and/or preventing ventricular flutter in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 50, or a composition of claim 51, or a medicament manufactured according to claim 52.

76. A method for treating atrial fibrillation in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 50, or a composition of claim 51, or a medicament manufactured according to claim 52.

77. A method for treating atrial flutter in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 50, or a composition of claim 51, or a medicament manufactured according to claim 52.

78. A method for treating ventricular fibrillation in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 50, or a composition of claim 51, or a medicament manufactured according to claim 52.

79. A method for treating ventricular flutter in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 50, or a composition of claim 51, or a medicament manufactured according to claim 52.

80. A method for preventing atrial fibrillation in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 50, or a composition of claim 51, or a medicament manufactured according to claim 52.

81. A method for preventing atrial flutter in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 50, or a composition of claim 51, or a medicament manufactured according to claim 52.

82. A method for preventing ventricular fibrillation in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 50, or a composition of claim 51, or a medicament manufactured according to claim 52.

83. A method for preventing ventricular flutter in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 50, or a composition of claim 51, or a medicament manufactured according to claim 52.

84. A method for treating and/or preventing arrhythmia in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof, an effective amount of a compound according to any one of claims 41 to 50.

85. A pharmaceutical composition comprising an amount of a compound according to claims 41 to 50 effective to treat and/or prevent atrial arrhythmia in a warm-blooded animal in need of the treatment and/or prevention, and a pharmaceutically acceptable carrier, diluent, or excipient.

86. A method for treating and/or preventing atrial arrhythmia in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to any one of claims 41 to 50.

87. A method for treating and/or preventing ventricular arrhythmia in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to any one of claims 41 to 50.

88. A pharmaceutical composition comprising an amount of a compound according to claims 41 to 50 effective to treat and/or prevent ventricular arrhythmia in a warm-blooded animal in need of the treatment and/or prevention, and a pharmaceutically acceptable carrier, diluent, or excipient.

89. A method for treating and/or preventing atrial fibrillation in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to any one of claims 41 to 50.

90. A method for treating and/or preventing atrial flutter in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to any one of claims 41 to 50.

91. A method for treating and/or preventing ventricular fibrillation in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to any one of claims 41 to 50.

92. A method for treating and/or preventing ventricular flutter in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to any one of claims 41 to 50.

93. A method for treating atrial fibrillation in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to any one of claims 41 to 50.

94. A method for treating atrial flutter in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to any one of claims 41 to 50.

95. A method for treating ventricular fibrillation in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to any one of claims 41 to 50.

96. A method for treating ventricular flutter in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to any one of claims 41 to 50.

97. A method for preventing atrial fibrillation in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to any one of claims 41 to 50.

98. A method for preventing atrial flutter in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to any one of claims 41 to 50.

99. A method for preventing ventricular fibrillation in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to any one of claims 41 to 50.

100. A method for preventing ventricular flutter in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to any one of claims 41 to 50.